Search Results

You are looking at 151 - 160 of 487 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Tami Borneman, Barbara F. Piper, Virginia Chih-Yi Sun, Marianna Koczywas, Gwen Uman, and Betty Ferrell

N Courtens AM Abu-Saad HH Schouten HC . Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature . Cancer Nurs 2002 ; 25 : 283 – 297 ; quiz 298–299 . 15. Payne JK . The trajectory of fatigue

Full access

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho

years, patients receiving CMV before surgery had a 16% reduction in mortality risk (hazard ratio, 0.84; 95% CI, 0.72–0.99; P =.037). Adjuvant Chemotherapy Data conflict regarding the role of adjuvant systemic chemotherapy in invasive bladder

Full access

Presenters: Alan P. Venook and Christopher G. Willett

,” wherein the patient undergoes long-course chemoradiotherapy (LCCRT) or short-course RT (SCRT) followed by surgery, then recovers to receive adjuvant chemotherapy. Due to some of the challenges with administering adjuvant chemotherapy in the postoperative

Full access

Andrea Angelo Martoni, Luigi Cavanna, and Gianpiero Porzio

Medicina non Convenzionale della Regione Emilia-Romagna.”) The primary objective was improvement of CRF, assessed as score reduction in the Brief Fatigue Inventory (BFI). 3 To be eligible, patients with no evidence of disease after adjuvant chemotherapy

Full access

Brian Badgwell

Syst Rev 2013 : CD008415 . 15. Earle CC Maroun JA . Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials . Eur J Cancer 1999 ; 35 : 1059 – 1064

Full access

Tara M. Mackay, Lennart B. van Rijssen, Jurr O. Andriessen, Mustafa Suker, Geert-Jan Creemers, Ferry A. Eskens, Ignace H. de Hingh, Lonneke V. van de Poll-Franse, Mirjam A.G. Sprangers, Olivier R. Busch, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W. van Laarhoven, and on behalf of the Dutch Pancreatic Cancer Group

postoperative clinical condition, adjuvant chemotherapy was offered. Palliative treatment was defined as any palliative systemic treatment of metastatic or locally advanced pancreatic or periampullary cancer. The start of treatment was defined as upfront surgery

Full access

Vivek Verma, Amy C. Moreno, Waqar Haque, Penny Fang, and Steven H. Lin

adjuvant chemotherapy in both pN1 and pN2 disease (with additional RT in the latter), this study does not support the routine administration of cCRT. In the absence of prospective data, it is readily acknowledged that retrospective selection biases may

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

statistically significant rate of increased pathCR, or improvement in rates of failure-free or overall survivals, when comparing neoadjuvant chemotherapy followed by chemoradiotherapy and then surgery and adjuvant chemotherapy versus chemoradiotherapy followed

Full access

Joleen M. Hubbard and Axel Grothey

older counterparts. Quah et al 11 found that 39% of patients aged 40 years or younger received adjuvant chemotherapy for stage II disease, compared with only 14% of older patients, even though the clinical and pathologic tumor characteristics were

Full access

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

approach to the disease. The utility of adjuvant chemotherapy after cystectomy remains highly contentious. Neoadjuvant therapy is also the subject of much discussion. Despite the existence of positive phase III data supporting this approach, it appears to